Trevena, Inc. (TRVN)
Trevena, Inc.
955 Chesterbrook Boulevard
Suite 110
Chesterbrook, PA 19087
United States
610 354 8840
https://www.trevena.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 23
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Carrie L. Bourdow | President, CEO & Chairman | 1M | N/D | 1963 |
| Mr. Barry Shin | Executive VP, COO & CFO | 670.02k | N/D | 1972 |
| Dr. Mark A. Demitrack M.D. | Senior VP & Chief Medical Officer | 690.32k | N/D | 1958 |
| Dr. Howard A. Rockman M.D. | Scientific Founder, Consultant and Member of Scientific Advisory Board | N/D | N/D | N/D |
| Mr. Joel Solomon | VP, General Counsel & Chief Compliance Officer | N/D | N/D | N/D |
| Mr. Michael Catalano | Vice President of Marketing | N/D | N/D | N/D |
| Mr. Robert T. Yoder | Senior VP, Chief Business Officer & Head of Commercial Operations | 490.64k | N/D | 1966 |
| Ms. Patricia M. Drake | Senior VP & Chief Commercial Officer | N/D | N/D | 1966 |
Descripción
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Gestión corporativa
La calificación ISS Governance QuickScore de Trevena, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
